LMQ Stock Chart & Stats
€0.01
<€0.01(20.00%)
At close: 4:00 PM EDT
€0.01
<€0.01(20.00%)
Day’s Range― - ―
52-Week Range<€0.01 - €0.05
Previous CloseN/A
Volume0.00
Average Volume (3M)0.00
Market Cap
€18.00M
Enterprise Value€7.45M
Total Cash (Recent Filing)€2.51M
Total Debt (Recent Filing)€4.28M
Price to Earnings (P/E)―
Beta-8.66
Next Earnings
Jan 26, 2027EPS EstimateN/A
Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)>-0.01
Shares Outstanding13,440,911,000
10 Day Avg. Volume0
30 Day Avg. Volume0
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)5.90
Price to Sales (P/S)6.02
P/FCF Ratio-0.85
Enterprise Value/Market CapN/A
Enterprise Value/RevenueN/A
Enterprise Value/Gross ProfitN/A
Enterprise Value/EbitdaN/A
Forecast
1Y Price TargetN/A
Price Target UpsideN/A
Rating ConsensusN/A
Number of Analyst Covering0
EPS Forecast (FY)>-0.01
Revenue Forecast (FY)€20.89K
Bulls Say, Bears Say
Bulls Say
Revenue GrowthRevenue growth of 33.37% indicates that Oxford BioDynamics is expanding demand for its offerings. If sustained, this growth can improve operating leverage, support investment in test commercialization, and increase the platform’s relevance with customers and partners over the next several quarters.
Proprietary Epigenetics PlatformThe EpiSwitch platform provides a differentiated technology base centered on chromatin-based biomarkers measured from blood samples. A proprietary diagnostic approach can support repeatable product development, strengthen intellectual property value, and create opportunities across precision medicine.
Multiple Monetization ChannelsOBD combines direct test and laboratory-service revenue with licensing, platform access, and research partnerships. This model creates several routes to commercialize the same technology, potentially broadening customer reach and reducing reliance on a single product or contract type.
Bears Say
Persistent UnprofitabilityNegative net, gross, and EBIT margins show that current revenue is not yet translating into sustainable profitability. Continued losses can constrain internal funding, require additional capital, and make it harder for the company to scale its diagnostic platform without improving cost efficiency.
High LeverageA debt-to-equity ratio of 4.58 indicates substantial reliance on debt relative to shareholder equity. Combined with negative returns and limited equity backing, this reduces financial flexibility, increases the importance of refinancing capacity, and can restrict investment in commercialization.
Pressured Cash GenerationDeclining free cash flow growth and negative operating cash flow relative to net income indicate that the business is not generating improving cash resources from operations. Persistent cash pressure may limit product development and increase dependence on external financing.
Oxford BioDynamics News
LMQ FAQ
What was Oxford BioDynamics PLC’s price range in the past 12 months?
Oxford BioDynamics PLC lowest stock price was <€0.01 and its highest was €0.05 in the past 12 months.
What is Oxford BioDynamics PLC’s market cap?
Oxford BioDynamics PLC’s market cap is €18.00M.
When is Oxford BioDynamics PLC’s upcoming earnings report date?
Oxford BioDynamics PLC’s upcoming earnings report date is Jan 26, 2027 which is in 140 days.
How were Oxford BioDynamics PLC’s earnings last quarter?
Oxford BioDynamics PLC released its earnings results on Jun 30, 2026. The company reported -€0.001 earnings per share for the quarter.
Is Oxford BioDynamics PLC overvalued?
According to Wall Street analysts Oxford BioDynamics PLC’s price is currently Overvalued.
Does Oxford BioDynamics PLC pay dividends?
Oxford BioDynamics PLC does not currently pay dividends.
What is Oxford BioDynamics PLC’s EPS estimate?
Oxford BioDynamics PLC’s EPS estimate for its next earnings report is not yet available.
How many shares outstanding does Oxford BioDynamics PLC have?
Oxford BioDynamics PLC has 13,440,911,000 shares outstanding.
What happened to Oxford BioDynamics PLC’s price movement after its last earnings report?
Oxford BioDynamics PLC reported an EPS of -€0.001 in its last earnings report. Following the earnings report the stock price went down -12.791%.
Which hedge fund is a major shareholder of Oxford BioDynamics PLC?
Currently, no hedge funds are holding shares in DE:LMQ
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Company Description
Oxford BioDynamics PLC
Oxford BioDynamics Plc operates as a biotechnology firm that specializes in identifying and advancing biomarkers, primarily for the pharmaceutical and biotechnology sectors across global markets, including the United States. Its flagship offering is EpiSwitch, an exclusive technological platform employed for discovering, assessing, validating, and tracking epigenetic biomarkers, specifically referred to as chromosome conformation signatures. These are crucial for developing medical diagnostic kits, predicting disease onset, aiding in diagnosis, and informing therapeutic strategies. The company's key products encompass the EpiSwitch CiRT (Checkpoint Inhibitor Response Test), a validated prognostic tool for forecasting patient responses to checkpoint inhibitor immunotherapy; the EpiSwitch CST (Covid Severity Test), a sophisticated blood test designed to predict the severity of COVID-19 in adults; and the EpiSwitch Explorer Array Kit, which enables high-resolution 3D genome analysis and novel biomarker discovery. Established in 2007, Oxford BioDynamics Plc maintains its headquarters in Oxford, United Kingdom.
Technical Analysis
IXICO plc
―
SkinBioTherapeutics
―
Fusion Antibodies Plc
―
Genflow Biosciences Plc
―
Aptamer Group Plc
―